Latest Kaiser Health News Stories
Due to poor doctor-patient communication, most people with advanced cancer don’t know enough about their disease to make vital decisions.
One insurer is turning the tables on drugmakers with what may be a new job category: a sales force for cost-effective medicine.
With the cost of medications up 300 percent in the past decade, supporters see this as a first step to rein in prices.
One in 9 Medicare enrollees have COPD and many of them can’t afford the inhalers that keep them out of the emergency room.
A new JAMA study examines how drug rebates can direct money to middlemen and force Medicare patients to cough up more money.
A new law gives Medicaid regulators power to threaten drugmakers with cost-effectiveness scrutiny unless they grant additional rebates.
With flawed systems for tracking the side effects of prescription drugs, a link between proton pump inhibitors and kidney disease suggested by research cannot be proven. Patients who swear by the drugs hope it won’t be.
Even the most exalted among us realize health care policy is complicated. Here’s a pop quiz to see what you have learned as a regular reader of Kaiser Health News.
A look at how and why strategic, star-studded advertising brought a drug for a little-known neurological condition into your home.
More than 70 drugs approved from 2001 through 2010 ran into safety concerns later that resulted in withdrawals from the market, “black box” warnings or other actions.
Several public health officials endorse using a federal law to slash hepatitis C drug prices in Louisiana and avoid drug bills that could cripple the state budget.
Senior citizens have to be patient and keep close records to appeal when Medicare plans refuse to cover their medicines.
Local health officials are bracing for the potential impact of a Trump administration policy that would stop federal funding to jurisdictions that don’t enforce federal immigration laws.
A California lawmaker wants to strengthen collaboration among public agencies to bring down costs to taxpayers.
Doctors and drug developers have a stake in making cancer treatments seem better than they really are.
Even as drug pricing issues continue to draw scrutiny, federal safety regulations and incentives offer drug companies a new avenue to get a sweet return on their development costs.
With high drug prices creating widespread controversy, top pharmaceutical companies and their trade group vastly increased their lobbying spending on Capitol Hill.
Two companies that faced criticism for high-priced drugs, Marathon and Mallinckrodt, have dropped out of the PhRMA trade association.
Led by Pfizer and Amgen, about 10 health care firms contributed to President Donald Trump’s inauguration, which earned them entry into private events with the president and vice president.
Kaiser Health News gives readers a chance to respond, react and comment on our stories.